CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests

Medicare Administrative Contractor Novitas Solutions released a local coverage determination last week limiting coverage for multiple cancer genetic tests, including those from Castle Biosciences, Interpace Biosciences, and Pacific Edge Diagnostics.

The contractor reviewed and analyzed published literature for multiple genetic tests for oncology and rescinded coverage for Castle Bio’s DecisionDx-Melanoma and DecisionDx-SCC tests, Pacific Edge Diagnostics’ Cxbladder Detect, Enhanced Detect, Monitor, Enhanced Triage, and Resolve assays, Interpace’s PancraGen, Clinical Genomics’ Colvera, Abbott’s UroVysion fluorescence in situ hybridization test, and the University of Pittsburgh Medical Center’s ThyroSeq Cancer Risk Classifier and PancreaSeq Genomic Classifier